Elizabeth A Mittendorf

Summary

Affiliation: Walter Reed Army Medical Center
Country: USA

Publications

  1. doi request reprint Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine
    Jarrod P Holmes
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, 3851 Roger Brooke Dr, Fort Sam Houston, TX, 78234, USA
    J Clin Oncol 26:3426-33. 2008
  2. ncbi request reprint Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy
    Elizabeth A Mittendorf
    Comprehensive Breast Center, Clinical Breast Care Project CBCP, Walter Reed Army Medical Center, Washington, DC 20307, USA
    Curr Surg 62:253-7. 2005
  3. ncbi request reprint Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides
    Elizabeth A Mittendorf
    Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Breast Cancer Res Treat 92:85-93. 2005
  4. doi request reprint Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    Asna Amin
    Department of Surgery, General Surgery Service, Walter Reed Army Medical Center, Washington, DC, USA
    Cancer Immunol Immunother 57:1817-25. 2008
  5. ncbi request reprint Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer
    Elizabeth A Mittendorf
    Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, 6900 Georgia Avenue NW, Washington, DC 20307 5001, USA
    Ann Surg Oncol 13:1085-98. 2006
  6. doi request reprint The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    Linda C Benavides
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, Houston, Texas 78234, USA
    Clin Cancer Res 15:2895-904. 2009
  7. doi request reprint Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04
    Mark G Carmichael
    Cancer Vaccine Development Program, United States Military Cancer Institute, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Cancer 116:292-301. 2010
  8. doi request reprint Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    George E Peoples
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas 78234, USA
    Clin Cancer Res 14:797-803. 2008
  9. doi request reprint Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines
    Linda C Benavides
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, 3851 Roger Brooke Drive, Ft Sam, Houston, TX 78234, USA
    Expert Rev Vaccines 10:201-10. 2011
  10. ncbi request reprint Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial
    Elizabeth A Mittendorf
    Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Cancer 106:2309-17. 2006

Collaborators

Detail Information

Publications27

  1. doi request reprint Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine
    Jarrod P Holmes
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, 3851 Roger Brooke Dr, Fort Sam Houston, TX, 78234, USA
    J Clin Oncol 26:3426-33. 2008
    ..We present the results of the first human phase I trial of the Ii-Key hybrid HER-2/neu peptide (AE37) vaccine in disease-free, node-negative breast cancer patients...
  2. ncbi request reprint Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy
    Elizabeth A Mittendorf
    Comprehensive Breast Center, Clinical Breast Care Project CBCP, Walter Reed Army Medical Center, Washington, DC 20307, USA
    Curr Surg 62:253-7. 2005
    ..The technique has also been applied successfully in patients with ductal carcinoma in situ (DCIS). The purpose of this study was to review our experience performing SLNB in patients with a biopsy diagnosis of DCIS...
  3. ncbi request reprint Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides
    Elizabeth A Mittendorf
    Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Breast Cancer Res Treat 92:85-93. 2005
    ..57%, respectively. These results correlated favorably with cytotoxicity as measured by the traditional (51)Cr assay. These findings confirm preliminary reports of the CD107 assay and suggest its usefulness for monitoring cancer trials...
  4. doi request reprint Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    Asna Amin
    Department of Surgery, General Surgery Service, Walter Reed Army Medical Center, Washington, DC, USA
    Cancer Immunol Immunother 57:1817-25. 2008
    ..We have performed clinical trials of E75 + GM-CSF vaccine in disease-free, node-positive and node-negative BCa patients at high recurrence risk and recurrences were noted in both control and vaccine groups...
  5. ncbi request reprint Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer
    Elizabeth A Mittendorf
    Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, 6900 Georgia Avenue NW, Washington, DC 20307 5001, USA
    Ann Surg Oncol 13:1085-98. 2006
    ..This study was designed to investigate the kinetics of trastuzumab treatment on tumor cells with varying levels of HER2/neu expression and to determine the effect of trastuzumab on HER2/neu-specific cytotoxic T lymphocyte-mediated lysis...
  6. doi request reprint The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    Linda C Benavides
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, Houston, Texas 78234, USA
    Clin Cancer Res 15:2895-904. 2009
    ..We have conducted clinical trials with the HER2/neu E75 peptide vaccine in breast cancer patients with varying levels of HER2/neu expression. Vaccine response based on HER2/neu expression level was analyzed...
  7. doi request reprint Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04
    Mark G Carmichael
    Cancer Vaccine Development Program, United States Military Cancer Institute, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Cancer 116:292-301. 2010
    ..GP2, derived from the transmembrane portion of HER-2/neu, has differing binding characteristics and may be more immunogenic than E75. Results of the first phase 1 trial of GP2 peptide vaccine are presented...
  8. doi request reprint Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    George E Peoples
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas 78234, USA
    Clin Cancer Res 14:797-803. 2008
    ..We have conducted two overlapping E75 vaccine trials to prevent recurrence in node-positive (NP) and node-negative (NN) breast cancer patients...
  9. doi request reprint Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines
    Linda C Benavides
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, 3851 Roger Brooke Drive, Ft Sam, Houston, TX 78234, USA
    Expert Rev Vaccines 10:201-10. 2011
    ..077) and GP2 (p = 0.076). All three peptide vaccines were safe and well-tolerated. These findings have led to a clinically relevant optimal vaccine dosing strategy, which may be applicable to other peptide-based cancer vaccines...
  10. ncbi request reprint Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial
    Elizabeth A Mittendorf
    Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Cancer 106:2309-17. 2006
    ..Importantly, a naturally occurring polymorphism (I-->V at position 2, 2VGP2) associated with increased breast cancer risk was addressed...
  11. doi request reprint The GP2 peptide: a HER2/neu-based breast cancer vaccine
    Kevin S Clive
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, Ft Sam Houston, Texas, USA
    J Surg Oncol 105:452-8. 2012
    ....
  12. ncbi request reprint Folate receptor α: a storied past and promising future in immunotherapy
    Guy T Clifton
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, Ft Sam Houston, TX, USA
    Hum Vaccin 7:183-90. 2011
    ..This review will cover immunotherapeutic methods, both active and passive, that target FRα...
  13. ncbi request reprint Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study
    Alexander Stojadinovic
    Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Ann Surg Oncol 14:3359-68. 2007
    ..Recent advances in the ability to quantify and phenotype circulating tumor cells (CTCs) in breast cancer patients may lead to a role for CTCs in monitoring response to vaccine-based immunotherapy...
  14. ncbi request reprint Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer
    Elizabeth A Mittendorf
    Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, 6900 Georgia Avenue NW, Washington, DC 20307 5001, USA
    Surgery 139:407-18. 2006
    ..The purpose of this study was to demonstrate clonal expansion of E75-specific CD8(+) T cells and to identify intra- and interantigenic epitope spreading...
  15. doi request reprint Cancer vaccines: should we be targeting patients with less aggressive disease?
    Diane F Hale
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, San Antonio, TX, USA
    Expert Rev Vaccines 11:721-31. 2012
    ..Data from these trials suggest that cancer vaccines may be more effective in patients with lower volume disease, and data from the E75 peptide vaccine trials suggest that vaccines may be most effective in less aggressive disease...
  16. ncbi request reprint Electrical impedance scanning as a new breast cancer risk stratification tool for young women
    Alexander Stojadinovic
    Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    J Surg Oncol 97:112-20. 2008
    ..The T-Scan(tm2000 (ED is designed to use EIS to identify women ages 30-39 with elevated risk of breast cancer (i.e., T-Scan+ women)...
  17. doi request reprint Surgical considerations in patients receiving neoadjuvant systemic therapy
    Akhil Chawla
    Department of Surgery, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH, USA
    Future Oncol 8:239-50. 2012
    ..An ongoing cooperative group trial is investigating the utility of sentinel lymph node surgery in the clinically node-positive population...
  18. ncbi request reprint Satisfaction with breast cancer screening and future screening participation
    Alexander Stojadinovic
    Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Med Sci Monit 13:CR422-9. 2007
    ....
  19. doi request reprint Staging of breast cancer in the neoadjuvant setting
    Jacqueline S Jeruss
    Department of Surgery, Northwestern University Feinberg School of Medicine and Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Cancer Res 68:6477-81. 2008
    ....
  20. ncbi request reprint Persistent parathyroid hormone elevation following curative parathyroidectomy for primary hyperparathyroidism
    Elizabeth A Mittendorf
    Department of Surgery, MetroHealth Medical Center, 2500 MetroHealth Dr, H920, Cleveland, OH 44109 1998, USA
    Arch Otolaryngol Head Neck Surg 128:275-9. 2002
    ..Persistent elevation of parathyroid hormone (PTH) levels following parathyroidectomy may indicate residual abnormal parathyroid tissue...
  21. ncbi request reprint Management of giant gastric ulcers: case report and review of the literature
    J Scott Kennedy
    Department of Surgery, Malcolm Grow Medical Center, 1050 West Perimeter Road, Andrews Air Force Base, Maryland, USA
    Curr Surg 61:220-3. 2004
  22. ncbi request reprint The results of ultrasound-guided fine-needle aspiration biopsy for evaluation of nodular thyroid disease
    Elizabeth A Mittendorf
    Department of Surgery, Uniformed Services, University of the Health Sciences, Bethesda, MD, USA
    Surgery 132:648-53; discussion 653-4. 2002
    ..The purpose of this study was to determine whether ultrasonography (US) improves the accuracy and reduces the rate of nondiagnostic fine-needle aspiration biopsy (FNAB) of thyroid nodules...
  23. doi request reprint Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    Jarrod P Holmes
    Department of Medicine, Division of Hematology and Medical Oncology, Naval Medical Center San Diego, San Diego, California, USA
    Cancer 113:1666-75. 2008
    ..The optimal biologic dose (OBD) was determined based on toxicity and immunologic response...
  24. doi request reprint The E75 HER2/neu peptide vaccine
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Immunol Immunother 57:1511-21. 2008
    ..Finally, we present some of the future directions for our Cancer Vaccine Development Program assessing multi-epitope peptide vaccines and combination immunotherapies...
  25. ncbi request reprint Significance and management of micrometastases in patients with breast cancer
    Elizabeth A Mittendorf
    The University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 7:1451-61. 2007
    ....
  26. ncbi request reprint Breast cancer vaccines: promise for the future or pipe dream?
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 110:1677-86. 2007
    ..A second strategy for a preventive breast cancer vaccine is to target tumor-associated antigens. Ongoing clinical trials are utilizing this approach, with preliminary results that are encouraging...
  27. ncbi request reprint Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy
    Jacqueline S Jeruss
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    J Clin Oncol 26:246-52. 2008
    ..We hypothesized that by using clinical and pathologic staging parameters, in conjunction with biologic tumor markers, a novel means of determining prognosis for patients treated with neoadjuvant chemotherapy could be facilitated...